Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Brief Summary: To demonstrate the effectiveness of DCV 3DAA fixed dose combination with or without Ribavirin in treatment naive cirrhotic subjects.


Options:
A: Arm Label: ABT-450/r/ABT-267 and ABT-333, plus RBV; Type: EXPERIMENTAL; Interventions: Drug: ABT-450/r/ABT-267, ABT-333, Drug: Ribavirin | Arm Label: Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV; Type: EXPERIMENTAL; Interventions: Drug: ABT-450/r/ABT-267, ABT-333, Drug: Ribavirin, Drug: Placebo for ABT-450/r/ABT-267, Drug: Placebo for ABT-333, Drug: Placebo for ribavirin | Intervention Type: DRUG; Name: ABT-450/r/ABT-267, ABT-333; Assigned to Arm(s): ABT-450/r/ABT-267 and ABT-333, plus RBV, Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): ABT-450/r/ABT-267 and ABT-333, plus RBV, Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV | Intervention Type: DRUG; Name: Placebo for ABT-450/r/ABT-267; Assigned to Arm(s): Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV | Intervention Type: DRUG; Name: Placebo for ABT-333; Assigned to Arm(s): Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV | Intervention Type: DRUG; Name: Placebo for ribavirin; Assigned to Arm(s): Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV
B: Arm Label: Placebo 12 Weeks (GT2/3); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to match SOF, Drug: Placebo to match RBV | Arm Label: SOF 12 Weeks (GT2/3); Type: EXPERIMENTAL; Interventions: Drug: SOF, Drug: RBV | Arm Label: SOF 24 Weeks (GT3); Type: EXPERIMENTAL; Interventions: Drug: SOF, Drug: RBV | Intervention Type: DRUG; Name: SOF; Assigned to Arm(s): SOF 12 Weeks (GT2/3), SOF 24 Weeks (GT3) | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): SOF 12 Weeks (GT2/3), SOF 24 Weeks (GT3) | Intervention Type: DRUG; Name: Placebo to match SOF; Assigned to Arm(s): Placebo 12 Weeks (GT2/3) | Intervention Type: DRUG; Name: Placebo to match RBV; Assigned to Arm(s): Placebo 12 Weeks (GT2/3)
C: Arm Label: A1: DCV/ASV/BMS-791325+Placebo matching RBV (naive); Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Asunaprevir, Drug: BMS-791325, Drug: Placebo matching Ribavirin | Arm Label: A2: DCV/ASV/BMS-791325 + RBV (naive); Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Asunaprevir, Drug: BMS-791325, Drug: Ribavirin | Arm Label: A3: DCV/ASV/BMS-791325+Placebo matching RBV (experienced); Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Asunaprevir, Drug: BMS-791325, Drug: Placebo matching Ribavirin | Arm Label: A4: DCV/ASV/BMS-791325 + RBV (experienced); Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Asunaprevir, Drug: BMS-791325, Drug: Ribavirin | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): A1: DCV/ASV/BMS-791325+Placebo matching RBV (naive), A2: DCV/ASV/BMS-791325 + RBV (naive), A3: DCV/ASV/BMS-791325+Placebo matching RBV (experienced), A4: DCV/ASV/BMS-791325 + RBV (experienced) | Intervention Type: DRUG; Name: Asunaprevir; Assigned to Arm(s): A1: DCV/ASV/BMS-791325+Placebo matching RBV (naive), A2: DCV/ASV/BMS-791325 + RBV (naive), A3: DCV/ASV/BMS-791325+Placebo matching RBV (experienced), A4: DCV/ASV/BMS-791325 + RBV (experienced) | Intervention Type: DRUG; Name: BMS-791325; Assigned to Arm(s): A1: DCV/ASV/BMS-791325+Placebo matching RBV (naive), A2: DCV/ASV/BMS-791325 + RBV (naive), A3: DCV/ASV/BMS-791325+Placebo matching RBV (experienced), A4: DCV/ASV/BMS-791325 + RBV (experienced) | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): A2: DCV/ASV/BMS-791325 + RBV (naive), A4: DCV/ASV/BMS-791325 + RBV (experienced) | Intervention Type: DRUG; Name: Placebo matching Ribavirin; Assigned to Arm(s): A1: DCV/ASV/BMS-791325+Placebo matching RBV (naive), A3: DCV/ASV/BMS-791325+Placebo matching RBV (experienced)
D: Arm Label: SOF/VEL 12 Weeks; Type: EXPERIMENTAL; Interventions: Drug: SOF/VEL | Arm Label: SOF+RBV 24 Weeks; Type: EXPERIMENTAL; Interventions: Drug: SOF, Drug: RBV | Intervention Type: DRUG; Name: SOF/VEL; Assigned to Arm(s): SOF/VEL 12 Weeks | Intervention Type: DRUG; Name: SOF; Assigned to Arm(s): SOF+RBV 24 Weeks | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): SOF+RBV 24 Weeks

Answer: C